Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sheard

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2013
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapyYin Liu, Hong-Wei Wu, Michael A Sheard, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2013
Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cellsMichael A Sheard, Shahab Asgharzadeh, Yin Liu, et al.
Blood|May 31, 2007
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivoMin H Kang, Yun Hee Kang, Barbara Szymanska, et al.
BMC Cancer|July 17, 2019
Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidednessBeatrix Bencsikova, Eva Budinska, Iveta Selingerova, et al.
Cancer Immunology, Immunotherapy : CII|August 29, 2013
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1Yibing Xu, Jianping Sun, Michael A Sheard, et al.
Cancer Research|May 2, 2013
Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastomaTasnim Ara, Rie Nakata, Michael A Sheard, et al.
International Journal of Cancer|April 18, 2018
Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytesMatthew W Webb, Jianping Sun, Michael A Sheard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2019
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer CellsHong-Wei Wu, Michael A Sheard, Jemily Malvar, et al.
Cancer Research|July 9, 2017
Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal CellsLucia Borriello, Rie Nakata, Michael A Sheard, et al.
Journal for Immunotherapy of Cancer|January 11, 2021
Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in miceMichael John Zobel, Abigail K Zamora, Hong-Wei Wu, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 5, 2013
Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapyYin Liu, Hong-Wei Wu, Michael A Sheard, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 31, 2013
Membrane-bound TRAIL supplements natural killer cell cytotoxicity against neuroblastoma cellsMichael A Sheard, Shahab Asgharzadeh, Yin Liu, et al.
Blood|May 31, 2007
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivoMin H Kang, Yun Hee Kang, Barbara Szymanska, et al.
BMC Cancer|July 17, 2019
Circulating T cell subsets are associated with clinical outcome of anti-VEGF-based 1st-line treatment of metastatic colorectal cancer patients: a prospective study with focus on primary tumor sidednessBeatrix Bencsikova, Eva Budinska, Iveta Selingerova, et al.
Cancer Immunology, Immunotherapy : CII|August 29, 2013
Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1Yibing Xu, Jianping Sun, Michael A Sheard, et al.
Cancer Research|May 2, 2013
Critical role of STAT3 in IL-6-mediated drug resistance in human neuroblastomaTasnim Ara, Rie Nakata, Michael A Sheard, et al.
International Journal of Cancer|April 18, 2018
Colony stimulating factor 1 receptor blockade improves the efficacy of chemotherapy against human neuroblastoma in the absence of T lymphocytesMatthew W Webb, Jianping Sun, Michael A Sheard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 10, 2019
Anti-CD105 Antibody Eliminates Tumor Microenvironment Cells and Enhances Anti-GD2 Antibody Immunotherapy of Neuroblastoma with Activated Natural Killer CellsHong-Wei Wu, Michael A Sheard, Jemily Malvar, et al.
Cancer Research|July 9, 2017
Cancer-Associated Fibroblasts Share Characteristics and Protumorigenic Activity with Mesenchymal Stromal CellsLucia Borriello, Rie Nakata, Michael A Sheard, et al.
Journal for Immunotherapy of Cancer|January 11, 2021
Initiation of immunotherapy with activated natural killer cells and anti-GD2 antibody dinutuximab prior to resection of primary neuroblastoma prolongs survival in miceMichael John Zobel, Abigail K Zamora, Hong-Wei Wu, et al.
Pageof 5